1-Bromo-10-cyclohexyldecane | 178670-96-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机溴化物
• 英文名称: 1-Bromo-10-cyclohexyldecane
• 英文别名: 10-Bromodecylcyclohexane
• CAS: 178670-96-7
• 化学式: C₁₆H₃₁Br
• 分子量: 303.326
• InChiKey: FSEAXFWBTIMRLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  17
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  二氯乙酸 、 1-Bromo-10-cyclohexyldecane 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以46%的产率得到2,2-Dichloro-12-cyclohexyl-dodecanoic acid
  参考文献：
  名称：

  ω-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents

  摘要：

  In screening experiments certain omega-substituted alkyl carboxylic acids were found to produce an increase in insulin-stimulated C-14-acetate incorporation into triglycerides, which may indicate an improvement in the action of insulin. Antidiabetic and lipid-lowering properties in genetically diabetic ob/ob mice demonstrated the in vivo relevance of the insulin-potentiating effects seen in vitro. The chemical structures of the w-substituted alkyl carboxylic acids with insulin-potentiating effects correspond to the general formula ring-spacer-COOH. A close structure-activity relationship was observed. The most potent compound in ob/ob mice was 3e, which normalized blood glucose as well as hyperinsulinaemia and lowered serum triglycerides and cholesterol by 52% and 37%, respectively. On the basis of these results, omega-substituted alkyl carboxylic acids are interesting as a new class of oral antidiabetic agents with insulin-sensitizing and lipid-lowering activity. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80029-4
• 作为产物：
  描述：

  溴代环己烷 、 1,10-二溴癸烷 在 CuCl2 、 ammonium chloride 、 magnesium 、 lithium chloride 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 1-Bromo-10-cyclohexyldecane
  参考文献：
  名称：

  2,2-Dichloroalkanecarboxylic acids, processes for their production and

  摘要：

  治疗糖尿病的药物，含有式I的化合物作为活性物质，其中A、B、A'和W具有索要权利要求书中所述的含义，以及式I的新化合物以及其生产方法。

  公开号：

  US05968982A1

文献信息

• Y‐Type Non‐Fullerene Acceptors with Outer Branched Side Chains and Inner Cyclohexane Side Chains for 19.36% Efficiency Polymer Solar Cells
  作者：Min Deng、Xiaopeng Xu、Yuwei Duan、Liyang Yu、Ruipeng Li、Qiang Peng

  DOI：10.1002/adma.202210760

  日期：2023.3

  non-fullerene acceptors of BTP-Cy-4F and BTP-Cy-4Cl are designed and synthesized by adopting outer branched side chains and inner cyclohexane side chains. An outstanding Voc of 0.937 V is achieved in the D18:BTP-Cy-4F binary blend devices along with a power conversion efficiency (PCE) of 18.52%. With the addition of BTP-eC9 to extend the absorption spectral coverage, a remarkable PCE of 19.36% is realized

  提高 Y 型非富勒烯受体的最低未占分子轨道 (LUMO) 能级可以提高开路电压 ( V oc )，从而提高当前性能最佳的聚合物太阳能电池 (PSC) 的光伏性能。L8-BO 的成功 Y6 衍生物证明了可行的路线之一，在外侧具有支链烷基链。这将引入空间位阻并减少分子间聚集，从而打开带隙并提高LUMO能级。为进一步利用空间位阻对Y6衍生物光电性能的影响，采用外支链和内环己烷侧链设计合成了两种Y型非富勒烯受体BTP-Cy-4F和BTP-Cy-4Cl链条。一个杰出的在 D18:BTP-Cy-4F 二元混合器件中实现了 0.937 V 的V oc以及 18.52% 的功率转换效率 (PCE)。通过添加 BTP-eC9 扩大吸收光谱覆盖范围，最终在相关三元共混器件中实现了 19.36% 的显着 PCE，这是目前单结 PSC 的最高值之​​一。结果表明环己烷侧链在构建高性能非富勒烯受体及其 PSC 方面具有巨大潜力。
• 2,2-DICHLORALKANCARBONSÄUREN, VERFAHREN ZU IHRER HERSTELLUNG DIESE ENTHALTENDE ARZNEIMITTEL, UND IHRE VERWENDUNG ZUR BEHANDLUNG DER INSULINRESISTENZ
  申请人：BOEHRINGER MANNHEIM GMBH

  公开号：EP0790824A1

  公开（公告）日：1997-08-27
• US5968982A
  申请人：——

  公开号：US5968982A

  公开（公告）日：1999-10-19
• [DE] 2,2-DICHLORALKANCARBONSÄUREN, VERFAHREN ZU IHRER HERSTELLUNG DIESE ENTHALTENDE ARZNEIMITTEL, UND IHRE VERWENDUNG ZUR BEHANDLUNG DER INSULINRESISTENZ<br/>[EN] 2,2-DICHLOROALKANE CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME, MEDICAMENT CONTAINING THE SAME, AND USE THEREOF FOR TREATING INSULIN RESISTANCE<br/>[FR] ACIDES 2,2-DICHLOROALCANECARBOXYLIQUES, LEUR PROCEDE DE PREPARATION, MEDICAMENTS LES CONTENANT, ET LEUR UTILISATION DANS LE TRAITEMENT DE LA RESISTANCE INSULINIQUE
  申请人：——

  公开号：WO1996015784A2

  公开（公告）日：1996-05-30

  [EN] A medicament for the treatment of diabetes mellitus contains as active substance a compound having the formula (I), in which A, B, A' and W have the meanings given in the description. Also disclosed are new compounds having the formula (I) and a process for preparing the same.
  [FR] L'invention concerne un médicament de traitement du diabète sucré qui contient comme principe actif un composé ayant la formule (I), dans laquelle A, B, A' et W ont la notation donnée dans les revendications, de nouveaux composés ayant la formule (I) et leur procédé de préparation.
  [DE] Arzneimittel zur Behandlung des Diabetes mellitus, die als Wirkstoff eine Verbindung der Formel (I) enthalten in der A, B, A' und W die in den Ansprüchen angegebene Bedeutung haben, neue Verbindungen der Formel (I) sowie Verfahren zu ihrer Herstellung.
• ω-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents
  作者：Kirstin Meyer、Edgar Voss、Richard Neidlein、Hans-Frieder Kühnle、Johannes Pill

  DOI：10.1016/s0223-5234(99)80029-4

  日期：1998.10

  In screening experiments certain omega-substituted alkyl carboxylic acids were found to produce an increase in insulin-stimulated C-14-acetate incorporation into triglycerides, which may indicate an improvement in the action of insulin. Antidiabetic and lipid-lowering properties in genetically diabetic ob/ob mice demonstrated the in vivo relevance of the insulin-potentiating effects seen in vitro. The chemical structures of the w-substituted alkyl carboxylic acids with insulin-potentiating effects correspond to the general formula ring-spacer-COOH. A close structure-activity relationship was observed. The most potent compound in ob/ob mice was 3e, which normalized blood glucose as well as hyperinsulinaemia and lowered serum triglycerides and cholesterol by 52% and 37%, respectively. On the basis of these results, omega-substituted alkyl carboxylic acids are interesting as a new class of oral antidiabetic agents with insulin-sensitizing and lipid-lowering activity. (C) Elsevier, Paris.